Human disease
Hutchinson-Gilford progeria syndrome
Mondo defines it as: “Hutchinson-Gilford progeria syndrome is a rare, fatal, autosomal dominant and premature aging disease, beginning in childhood and characterized by growth reduction, failure to thrive, a typical facial appearance (prominent forehead, protuberant eyes, thin nose with a beaked tip, thin lips, micrognathia and protruding ears) and distinct dermatologic features (generalized alopecia, aged-looking skin, sclerotic and dimpled skin over the abdomen and extremities, prominent cutaneous vasculature, dyspigmentation, nail hypoplasia and loss of subcutaneous fat).”
1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 1213 | Premature senesence | OMIA's OMIM numbers | 2 | Target evidence |
83.0
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
| Human gene | Score | Evidence |
|---|---|---|
| LMNA | 0.83 | 1,388 |
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Lonafarnib | None of these genes | Approved |
| Pravastatin | None of these genes | Phase 2 |
| Progerinin | None of these genes | Phase 2 |
| Zoledronic Acid Anhydrous | None of these genes | Phase 2 |
| Autologous Cord Blood | None of these genes | Phase 1/2 |
| Everolimus | None of these genes | Phase 1/2 |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.